Impact of highly active antiretroviral therapy (HAART) on the incidence of opportunistic infections, hospitalizations and mortality among children and adolescents living with HIV/AIDS in Belo Horizonte, Minas Gerais State, Brazil

Cadernos de Saude Publica

Volumn 23, Issue SUPPL. 3, 2007, Pages

  Candiani, Talitah M S ^a   Pinto, Jorge ^a   Cardoso, Claudete A Araújo ^a   Carvalho, Inácio R ^a   Dias, Arlete C M ^a   Carneiro, Mariângela ^a   Goulart, Eugênio A ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Highly active antiretroviral therapy; HIV; Oppurtunist infections

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; AIDS RELATED COMPLEX; ARTICLE; BRAZIL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EPIDEMIOLOGY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; INFANT; MALE; MORTALITY; PRESCHOOL CHILD; STATISTICS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; CHILD; CHILD, PRESCHOOL; EPIDEMIOLOGIC METHODS; FEMALE; HOSPITALIZATION; HUMANS; INFANT; MALE;

EID: 36849010284     PISSN: 0102311X     EISSN: 16784464     Source Type: Journal    
DOI: 10.1590/S0102-311X2007001500009     Document Type: Article

References (31)

1. Dankner WM, Lindsey JC, Levin MJ. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J 2001; 20:40-8.
2. Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA 1998; 280:72-7.
3. Lederman MM, Valdez H. Immune restoration with antiretroviral therapies: implications for clinical management. JAMA 2000; 284:223-8.
4. Chakraborty R. Infections and other causes of death in HIV-infected children in Africa. Paediatr Respir Rev 2004; 5:132-9.
5. Dufour V, Cadranel J, Wislez M, Lavole A, Bergot E, Parrot A, et al. Changes in the pattern of respiratory diseases necessitating hospitalization of HIV-infected patients since the advent of highly active antiretroviral therapy. Lung 2004; 182:331-41.
6. Canani RB, Spagnuolo MI, Cirillo P, Guarino A. Decreased needs for hospital care and antibiotics in children with advanced HIV-1 disease after protease inhibitor-containing combination therapy. AIDS 1999; 13:1005-6.
7. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997; 11:1731-8.
8. Sterling TR, Chaisson RE, Keruly J, Moore RD. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. J Infect Dis 2003; 188:1659-65.
9. Ministério da Saúde. Critérios de definição de casos de AIDS em adultos e crianças. Brasília: Ministério da Saúde; 2004.
10. Centers for Disease Control and Prevention. Revised classification system of human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep 1994; 43:1-10.
11. Szklo M, Niel F. Epidemilogy: beyond the basies. Frederick: Aspen Publishers; 2000.
12. Bernard P, Lapoint C. Mesures statistiques en épidé miologie. Québec: Université du Québec; 1987.
13. Coordenação Nacional de DST/AIDS. Boletim Epidemiológico AIDS 2003; Ano XVI, no. 1.
14. Fallo AA, Dobrzanski-Nisiewicz W, Sordelli N, Cattaneo MA, Scott G, Lopez EL. Clinical and epidemiologic aspects of human immunodeficiency virus-1-infected children in Buenos Aires, Argentina. Int J Infect Dis 2002; 6:9-16.
15. Spira R, Lepage P, Msellati P, Van De Perre P, Leroy V, Simonon A, et al. Natural history of human immunodeficiency virus type 1 infection in children: a five-year prospective study in Rwanda. Mother-to-Child HIV-1 Transmission Study Group. Pediatrics 1999;104:e56.
16. Marins JR, Jamal LF, Chen SY, Barros MB, Hudes ES, Barbosa AA, et al. Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS 2003; 17:1675-82.
17. Matida LH, Marcopito LF. O aumento do tempo de sobrevida das crianças com AIDS - Brasil. Boletim Epidemiológico AIDS 2002; Ano XV, no. 1. p. 49-55.
18. Detels R, Tarwater P, Phair JP, Margolick J, Riddler SA, Munoz A. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001; 15:347-55.
19. Dromer F, Mathoulin-Pelissier S, Fontanet A, Ronin O, Dupont B, Lortholary O. Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS 2004; 18:555-62.
20. Nachman S, Gona P, Dankner W, Weinberg A, Yogev R, Gershon A, et al. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Pediatrics 2005; 115:e488-94.
21. Schmidt-Westhausen AM, Priepke F, Bergmann FJ, Reichart PA. Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy. J Oral Pathol Med 2000; 29:336-41.
22. Chantry C. Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infection. Pediatric Infect Dis J 2003; 22:1033-8.
23. Finkelstein DM, Williams PL, Molenberghs G, Feinberg J, Powderly WG, Kahn J, et al. Patterns of opportunistic infections in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:38-45.
24. Chaisson RE, Gallant JE, Keruly JC, Moore RD. Impact of opportunistic disease on survival in patients with HIV infection. AIDS 1998; 12:29-33.
25. Holmes CB, Losina E, Walensky RP, Yazdanpanah Y, Freedberg KA. Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa. Clin Infect Dis 2003; 36:652-62.
26. Powderly WG. The interaction of opportunistic infections and HIV replication. AIDS 1999; 13:1603-6.
27. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999; 282:2220-6.
28. Granados JMS, Amador JTR, Miguel SF, Tome MIG, Conejo PR, Vivas PF, et al. Impact of highly active antiretroviral therapy on the morbility and mortality in Spanish human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003; 22:863-7.
29. Viani RM, Araneta MR, Deville JG, Spector SA. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis 2004; 39:725-31.
30. Mocroft A, Monforte A, Kirk O, Johnson MA, Friis-Moller N, Banhegyi D, et al. Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study. HIV Med 2004; 5:437-47.
31. Cohen J, West AB, Bini EJ. Infectious diarrhea in human immunodeficiency virus. Gastroenterol Clin North Am 2001; 30:637-64.